Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NUVL NASDAQ:PCVX NASDAQ:PHVS NYSE:QGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNUVLNuvalent$102.30-2.0%$102.13$70.25▼$113.01$8.08B1.15561,637 shs798,462 shsPCVXVaxcyte$52.39-2.1%$57.50$29.08▼$65.00$7.57B1.31.46 million shs1.29 million shsPHVSPharvaris$30.40-1.0%$28.14$15.46▼$33.33$1.99B-2.34400,033 shs444,227 shsQGENQiagen$33.00-0.9%$39.08$32.53▼$57.81$6.80B0.642.52 million shs1.80 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNUVLNuvalent0.00%-2.83%-1.50%+1.47%+44.04%PCVXVaxcyte0.00%-1.17%-15.77%-3.16%+78.08%PHVSPharvaris0.00%+1.03%+5.63%+14.93%+89.17%QGENQiagen0.00%-0.13%-19.40%-34.58%-23.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNUVLNuvalent$102.30-2.0%$102.13$70.25▼$113.01$8.08B1.15561,637 shs798,462 shsPCVXVaxcyte$52.39-2.1%$57.50$29.08▼$65.00$7.57B1.31.46 million shs1.29 million shsPHVSPharvaris$30.40-1.0%$28.14$15.46▼$33.33$1.99B-2.34400,033 shs444,227 shsQGENQiagen$33.00-0.9%$39.08$32.53▼$57.81$6.80B0.642.52 million shs1.80 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNUVLNuvalent0.00%-2.83%-1.50%+1.47%+44.04%PCVXVaxcyte0.00%-1.17%-15.77%-3.16%+78.08%PHVSPharvaris0.00%+1.03%+5.63%+14.93%+89.17%QGENQiagen0.00%-0.13%-19.40%-34.58%-23.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNUVLNuvalent 2.88Moderate Buy$137.2534.16% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0064.15% UpsidePHVSPharvaris 2.69Moderate Buy$49.1861.78% UpsideQGENQiagen 2.50Moderate Buy$46.3840.53% UpsideCurrent Analyst Ratings BreakdownLatest PHVS, NUVL, PCVX, and QGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026PHVSPharvaris UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$74.005/13/2026PHVSPharvaris Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$75.00 ➝ $74.005/12/2026QGENQiagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/7/2026QGENQiagen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$46.00 ➝ $40.004/30/2026QGENQiagen Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.004/29/2026QGENQiagen BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$44.00 ➝ $38.004/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Outperform$53.00 ➝ $43.004/29/2026QGENQiagen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy$43.004/29/2026QGENQiagen JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$60.00 ➝ $45.004/29/2026QGENQiagen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$55.00 ➝ $38.00(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNUVLNuvalentN/AN/AN/AN/A$14.87 per shareN/APCVXVaxcyteN/AN/AN/AN/A$20.75 per shareN/APHVSPharvarisN/AN/AN/AN/A$4.23 per shareN/AQGENQiagen$2.10B3.24$3.41 per share9.69$16.17 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%N/APCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)PHVSPharvaris-$198.79M-$3.18N/AN/AN/AN/A-67.56%-61.13%N/AQGENQiagen$424.88M$1.9117.2412.273.2819.16%14.40%8.40%8/4/2026 (Estimated)Latest PHVS, NUVL, PCVX, and QGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PHVSPharvaris-$0.8219-$0.70+$0.1219-$0.69N/AN/A5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A4/3/2026Q4 2025PHVSPharvaris-$0.69-$0.84-$0.15-$0.84N/AN/A2/24/2026Q4 2025PCVXVaxcyte-$1.46-$1.80-$0.34-$1.80$18.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNUVLNuvalentN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/AQGENQiagen$0.351.06%N/A18.32%N/ALatest PHVS, NUVL, PCVX, and QGEN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNUVLNuvalentN/A16.1415.27PCVXVaxcyteN/A7.497.49PHVSPharvarisN/A11.2410.11QGENQiagen0.493.213.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNUVLNuvalent97.26%PCVXVaxcyte96.78%PHVSPharvarisN/AQGENQiagen70.00%Insider OwnershipCompanyInsider OwnershipNUVLNuvalent5.02%PCVXVaxcyte3.10%PHVSPharvaris11.84%QGENQiagen9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNUVLNuvalent4079.00 million75.03 millionOptionablePCVXVaxcyte160144.40 million139.92 millionOptionablePHVSPharvaris3065.41 million57.66 millionNot OptionableQGENQiagen5,654206.08 million187.53 millionOptionablePHVS, NUVL, PCVX, and QGEN HeadlinesRecent News About These CompaniesQIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V.May 15 at 10:47 AM | globenewswire.comQGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential ...May 15 at 1:28 AM | caledonianrecord.comCQiagen NV (QGEN) price target decreased by 13.91% to 46.28May 15 at 1:28 AM | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 14 at 10:20 PM | prnewswire.comQGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsMay 14 at 7:00 PM | globenewswire.comLevi & Korsinsky Announces Investigation of Securities Claims Against Qiagen N.V. (QGEN)May 14 at 9:00 AM | globenewswire.comQIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 MillionMay 13, 2026 | businesswire.comQiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comQIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General MeetingMay 12, 2026 | businesswire.comDeciphering Qiagen (QGEN) International Revenue TrendsMay 11, 2026 | zacks.comLost Money on Qiagen N.V. (QGEN)? Contact Levi & Korsinsky to Protect Your RightsMay 10, 2026 | newsfilecorp.comNQiagen (NYSE:QGEN) Hits New 1-Year Low - Time to Sell?May 10, 2026 | americanbankingnews.comQiagen N.V. (QGEN) Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing - SlideshowMay 9, 2026 | seekingalpha.comM&T Bank Corp Takes $2.19 Million Position in Qiagen N.V. $QGENMay 9, 2026 | marketbeat.comQiagen (NYSE:QGEN) Valuation Check After Extended Share Price WeaknessMay 8, 2026 | finance.yahoo.comQiagen N.V. (QGEN) Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing TranscriptMay 8, 2026 | seekingalpha.comQiagen (QGEN) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comQiagen (NYSE:QGEN) Sets New 12-Month Low - Should You Sell?May 8, 2026 | marketbeat.comQiagen Files U.S. GAAP Quarterly Report for First Quarter 2026May 8, 2026 | tipranks.comQIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB TestingMay 7, 2026 | finance.yahoo.comQGEN SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Qiagen for Possible Securities Law ViolationsMay 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHVS, NUVL, PCVX, and QGEN Company DescriptionsNuvalent NASDAQ:NUVL$102.30 -2.11 (-2.02%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$102.34 +0.05 (+0.04%) As of 05/15/2026 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Vaxcyte NASDAQ:PCVX$52.39 -1.14 (-2.13%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$51.20 -1.19 (-2.27%) As of 05/15/2026 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Pharvaris NASDAQ:PHVS$30.40 -0.30 (-0.98%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$30.43 +0.03 (+0.10%) As of 05/15/2026 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Qiagen NYSE:QGEN$33.00 -0.29 (-0.86%) Closing price 05/15/2026 03:59 PM EasternExtended Trading$32.98 -0.02 (-0.07%) As of 05/15/2026 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
